Professionals 223 Users Online

Lipopolysaccharides Immunoassay Market

Market Study on Lipopolysaccharides Immunoassays: Kits & Reagents Account for Around Two-thirds Market Share

Lipopolysaccharides Immunoassay Market Segmented By Immunoassay Kits & Reagents, Analysers & Instruments, Consumables, Software Product Type ELISA, FIA, CLIA, LFA Assay for Research Use Only, Clinical Use Purpose

Lipopolysaccharides Immunoassay Market Outlook (2022-2032)

Worldwide revenue from the lipopolysaccharides immunoassay market reached US$ 1.3 Bn at the end of 2021, with the global market estimated to increase at a value CAGR of 3.2% to reach US$ 1.9 Bn by the end of 2032.

As assessed by Persistence Market Research, lipopolysaccharides immunoassay kits & reagents accounted for a market value of US$ 859.1 Mn in 2021. Overall, lipopolysaccharides immunoassay sales accounted for approximately 4.8% revenue share of the global immunoassay market at the end of 2021.

Report Attribute Details

Lipopolysaccharides Immunoassay Market Size (2022)

US$ 1.4 Bn

Projected Market Value (2032)

US$ 1.9 Bn

Global Market Growth Rate (2022-2032)

3.2% CAGR

Market Share of Top 5 Countries


Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Sales Analysis of Lipopolysaccharides Immunoassays (2012 to 2021) Vs. Market Outlooks (2022 to 2032)

The global market for lipopolysaccharides immunoassays recorded a CAGR of 1.7% in the last 9 years (2012 to 2021).

A bacterial toxin called lipopolysaccharide (LPS) is serologically reactive, and as little as 1 to 2 mg administered intravenously can be fatal. Through intestinal absorption of the lipopolysaccharide made by gut bacteria, lipopolysaccharide can reach the bloodstream.

The immune system mounts a rapid response to lipopolysaccharide, a strong pyrogen. Since many dietary items, supplements, and probiotics include gram-negative bacteria or lipopolysaccharide, they can be harmful to health.

Although these items are susceptible to digestion when consumed orally, they pose a health concern for people who have gastrointestinal conditions. In addition, pharmaceutical preparations such as parenteral medication products can introduce lipopolysaccharide into the human body, activating the complement system via a different pathway and potentially killing a person.

These circumstances have led to strong demand for the products offered in the lipopolysaccharides immunoassay market, and it is anticipated that this demand will increase over the coming years.

Moreover, lipopolysaccharide has been tested using ELISAs, which are based on the interaction between an antigen and an antibody. Lipopolysaccharide detection offers a way for identifying Escherichia coli in the food sector, an organism frequently connected with food-borne infections, in addition to medical diagnostics.

Successful lipopolysaccharide detection techniques combine sensitive detection platforms. Limulus Amebocyte Lysate (LAL) assays are used to monitor the presence of lipopolysaccharide in pharmaceutical items and medical devices.

Due to the wide range of applications of lipopolysaccharide immunoassays, the market is anticipated to expand at a CAGR of 3.2% to reach US$ 1.9 Bn, by the end of 2032.


Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

How Can Lipopolysaccharides Immunoassay Product Manufacturers Grow?

LPS Detection through Point-of-Care Testing

The market for lipopolysaccharides immunoassays is set to present opportunistic growth opportunities. This growth is associated with the development of point-of-care test kits for lipopolysaccharide immunoassays. This approach finds application in several industries, including dentistry.

A bacterial infection-induced chronic inflammation, termed as periodontal disease, could cause gum disease and tooth loss. The gram-negative oral anaerobe P. gingivalis produces lipopolysaccharide, which promotes the synthesis of inflammatory biomarkers, causing considerable host responses in gingival tissue.

Additionally, given the strong association between P. gingivalis and other severe health disorders such as cardiovascular disease as well as the neurodegenerative Alzheimer's disease that has recently emerged, quantitative determination of lipopolysaccharide from this bacteria has become a critical marker in dental health as well as in the overall body health system.

With several potential applications, the detection of LPS with lipopolysaccharide immunoassays is expected to be driven over the coming years. The growing emergence of infectious disease burden would be a prime propelling factor for this growth.

Thus, given the growing importance of P. gingivalis LPS, there is a significant market need for a novel point-of-care technology that can be used for both, early diagnosis and routine PG LPS level monitoring. The well-known PCR approach is typically used in the traditional qualitative identification of bacterial biomarkers, which necessitates educated workers and substantially more time in a laboratory setting.

One of the most promising point-of-care platforms is lateral flow assays, which have a number of advantages such as low cost, simple fabrication process, user-friendly colorimetric interface, quick turnaround, and no requirement for external instruments. These factors represent a lucrative growth outlook for the segment and the market.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

How is Demand for Lipopolysaccharides Immunoassays Being Affected?

Lack of Identified Library for Lipopolysaccharides

The inability to establish screening assays for multiple lipopolysaccharide antigens limits them from being employed for lipopolysaccharide detection, which further affects the accessibility of specific antibodies. As a result, techniques for selecting tailored antibodies need to be enhanced.

Additionally, although there are some variances, ELISA plates are generally functionalized with full dead bacteria for screening monoclonal antibody cultures, yielding potentially cross-reactive clones, which are subsequently screened against a variety of bacterial strains. Even among the numerous E. coli serotypes, it is observed that it is impossible to screen clones against every lipopolysaccharide epitope.

Moreover, for the detection of lipopolysaccharides, several sophisticated techniques have been developed, including the use of lipid bilayers, waveguide technology, aptamers, anti-microbials, synthetic polymers, optical immunoassays, electrochemical impedance spectroscopy (EIS), and in vitro assays. The availability of alternate methods of lipopolysaccharide detection hampers the growth of the overall lipopolysaccharides immunoassay market.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Country-wise Insights

Why is the U.S. Lipopolysaccharides Immunoassay Market a Lucrative One?

“Increasing Incidence of Chronic & Infectious Diseases”

The U.S. accounted for 30.3% market share in the global lipopolysaccharides immunoassay market in 2021, and a similar trend is expected over the forecast period as well.

This can be attributed to two factors: the ready availability of technologically-advanced diagnostics and the rising demand for diagnostics spurred by the increase in cancer cases.

The high prevalence of infectious diseases, including HIV, TB, and influenza, in the country, is also driving the demand for diagnosis and treatment.

How is the Market Shaping Up in Germany?

“Biopharmaceutical industry Driving Demand for Lipopolysaccharides Immunoassays”

Germany held around 6% share of the global lipopolysaccharides immunoassay market in 2021.

Numerous well-established players in Germany are actively conducting clinical studies to gauge the effectiveness of biopharmaceutical products intended for human use. The market utilizes lipopolysaccharide immunoassays for the same, and it is anticipated that the growth shown in the country for LPA immunoassays would gain pace over the coming years.

Why is China Emerging as a Prominent Market for Lipopolysaccharides Immunoassay Services?

“Large Population Base Necessitating Efficient Infectious Disease Diagnosis”

China held a share of 8.1% of the global lipopolysaccharides immunoassay market in 2021.

The proliferation of novel coronavirus infections in the country obliged the efforts toward the manufacturing of immunoassay kits & reagents for the assessment of pathogens, to initiate recovery.

With a large population base, the country displays a high growth potential for the sales of lipopolysaccharide immunoassay products, there suggesting lucrative growth opportunities for market growth in the country.

Category-wise Insights

Which Product Type is Driving High Market Growth?

“High Need for Clinical Research & Infectious Disease Diagnostics”

The immunoassay kits & reagents segment held around 64% share of the total lipopolysaccharides immunoassay market in 2021.

Infectious disease testing has gained traction ever since the advent of the novel coronavirus pandemic in 2020. The production and sales of immunoassay kits & reagents have thus seen an incline, and the segment is set to exhibit high growth traction over the forecast years due to advancements in clinical research practices.

Why are Lateral Flow Immunoassays Most Widely Used?

“Greater Efficacy of Lateral Flow Immunoassays”

The LFA segment holds the highest market share of around 39%.

Since lateral flow immunoassays can semi-quantitatively and rapidly identify individual biomarkers with a lower sensitivity, they have become the industry leader for lipopolysaccharides immunoassays.

For What Purpose is Sales Lipopolysaccharides Immunoassays Gaining Traction?

“Evaluation of LPS for Diagnostic Assessment”

Clinical use holds the highest market value share of around 82.2% in the global market for lipopolysaccharides immunoassays.

For clinical research, the detection of lipopolysaccharides is essential in understanding the biosynthesis of LPS in the human body, as well as its metabolism, physiology, and toxicity.

Competitive Landscape

To meet the unmet needs of patients, major companies are engaged in broad strategic activities in the field of immunoassays, such as mergers and acquisitions, development of innovative products, and geographical expansion.

For instance:

  • In May 2021, Response Biomedical launched the COVID-19 (SARS-CoV-2) antigen test for countries accepting the CE mark, to support the growing demand for testing.
  • In February 2021, Thermo Fisher Scientific partnered with Mindray on clinical chemistry analyzers for use with drugs of abuse immunoassays.

Lipopolysaccharides Immunoassay Industry Report Scope



Forecast Period


Historical Data Available for


Market Analysis

USD Million for Value

Key Countries Covered

  • U.S.
  • Canada
  • Brazil
  • Argentina
  • Mexico
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Russia
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Turkey
  • GCC
  • North Africa
  • South Africa

Key Market Segments Covered

  • Product Type
  • Assay
  • Purpose
  • Application
  • End User
  • Region

Key Companies Profiled

  • BioChek(BIOTECON Diagnostics)
  • AdVnt Biotechnologies
  • Fisher Scientific (THERMO)
  • Bio-Techne
  • Response Biomedical
  • New Horizons Diagnostic Corporation

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Key Segments of Lipopolysaccharides Immunoassay Industry Research

Lipopolysaccharides Immunoassay Market by Product Type:

  • Immunoassay Kits & Reagents
    • Kits
    • Primary Antibodies
    • Secondary Antibodies
    • Immunoassay Substrates
    • Immunoassay Buffers
  • Analysers & Instruments
  • Consumables
  • Software

Lipopolysaccharides Immunoassay Market by Assay:

  • FIA
  • CLIA
  • LFA
  • Others

Lipopolysaccharides Immunoassay Market by Purpose:

  • Research Use Only
  • Clinical Use

Lipopolysaccharides Immunoassay Market by Application:

  • Clinical Diagnostics
  • Drug Discovery
  • Screening of diseases & disorders

Lipopolysaccharides Immunoassay Market by End User:

  • Human Use
  • Veterinary

Lipopolysaccharides Immunoassay Market by Region:

  • North America Lipopolysaccharides Immunoassay Market
  • Latin America Lipopolysaccharides Immunoassay Market
  • Europe Lipopolysaccharides Immunoassay Market
  • South Asia Lipopolysaccharides Immunoassay Market
  • East Asia Lipopolysaccharides Immunoassay Market
  • Oceania Lipopolysaccharides Immunoassay Market
  • The Middle East & Africa Lipopolysaccharides Immunoassay Market

- Companies Covered in This Report -

  • BioChek(BIOTECON Diagnostics)
  • AdVnt Biotechnologies
  • Fisher Scientific (THERMO)
  • Bio-Techne.
  • Response Biomedical
  • New Horizons Diagnostic Corporation

- Frequently Asked Questions -

The global lipopolysaccharides immunoassay market was valued at US$ 1.3 Bn in 2021.

Sales of lipopolysaccharides immunoassays are set to increase at 3.2% CAGR and reach US$ 1.9 Bn by 2032.

Demand for lipopolysaccharides immunoassays increased at 1.7% CAGR from 2012 to 2021.

North America is set to exhibit a CAGR of 3.6% during the forecasted years.

The U.K. market held 5.1% share of the global lipopolysaccharides immunoassay market in 2021.

The U.S., China, Japan, Germany, and U.K. account for most demand for lipopolysaccharides immunoassays, currently holding 56.7% market share.

AdVnt Biotechnologies, Fisher Scientific (THERMO), and Bio-Techne are the top three manufacturers of lipopolysaccharides immunoassay products.

China held a share of 8.1% in the global lipopolysaccharides immunoassay market in 2021.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate